Related Experiment Video
Updated: Jun 21, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial
Nassir F Marrouche1, Johannes Brachmann,
1University of Utah, Division of Cardiology, School of Medicine, Salt Lake City, Utah 84132, USA. nassir.marrouche@hsc.utah.edu
Insights
Catheter ablation for atrial fibrillation (AF) in heart failure patients significantly reduces mortality and hospitalizations. This treatment offers a promising alternative to conventional care for improved patient outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Pulmonary vein isolation via catheter ablation is an emerging treatment for atrial fibrillation (AF).
- This modality is increasingly utilized in patients experiencing heart failure.
Purpose of the Study:
- To evaluate the efficacy of catheter ablation versus standard treatment in patients with left ventricular dysfunction and AF.
- To assess the impact of ablation on mortality and heart failure hospitalizations.
Main Methods:
- The CASTLE-AF trial is a randomized study involving 420 patients.
- Patients will be followed for a minimum of 3 years across international sites.
- The primary endpoint is a composite of all-cause mortality or worsening heart failure requiring hospitalization.
Main Results:
- Results are pending as the study is ongoing.
- The trial aims to determine if ablation improves survival and reduces heart failure events compared to conventional therapy.
Conclusions:
- The study will provide crucial data on the role of catheter ablation in managing AF in heart failure patients.
- Findings are expected to influence clinical guidelines for this patient population.
Background:
Electrical isolation of the pulmonary veins by catheter ablation is an emerging treatment modality for the treatment of atrial fibrillation (AF) and is increasingly used in patients with heart failure.
Methods:
The catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation trial (CASTLE-AF) is a randomized evaluation of ablative treatment of atrial fibrillation in patients with left ventricular dysfunction. The primary endpoint is the composite of all-cause mortality or worsening of heart failure requiring unplanned hospitalization using a time to first event analysis. Secondary endpoints are all-cause mortality, cardiovascular mortality, cerebrovascular accidents, worsening of heart failure requiring unplanned hospitalization, unplanned hospitalization due to cardiovascular reason, all-cause hospitalization, quality of life, number of therapies (shock and antitachycardia pacing) delivered by the implantable cardioverter-defibrillator (ICD), time to first ICD therapy, number of device-detected ventricular tachycardia and ventricular fibrillation episodes, AF burden, AF free interval, left ventricular function, exercise tolerance, and percentage of right ventricular pacing. CASTLE-AF will randomize 420 patients for a minimum of 3 years at 48 sites in the United States, Europe, Australia, and South America.
Related Concept Videos
Cardiac Catheterization III: Left Heart Catheterization
Cardiac Catheterization II: Right Heart Catheterization
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias VI: Management of Dysrhythmias
Cardiac Catheterization I: Pre-Procedure Overview

